SS-31, a four-amino-acid peptide already approved for a rare inherited heart disease, cut the share of irradiated heart-muscle cells showing a marker of premature aging from 67 percent to 38 percent in a new laboratory study.
The result, published online July 15 in the Journal of Radiation Research ↗, points at a problem cancer patients live with quietly. Radiation therapy aimed at a chest tumor also passes through the heart, and so does accidental radiation exposure. One of the ways radiation injures heart tissue is by pushing heart-muscle cells into senescence, a state where a cell stops dividing but does not die and instead sits in the tissue leaking inflammatory signals. There is no approved way to stop it.
What the peptide is
The peptide is elamipretide ↗, sold as Forzinity and known in the lab as SS-31. It is a synthetic string of four amino acids that homes to the inner membrane of mitochondria, the compartments that turn food and oxygen into usable energy, and binds a lipid there called cardiolipin. Stabilizing that membrane keeps the mitochondria running cleanly. The US Food and Drug Administration approved elamipretide earlier for Barth syndrome, a rare inherited disorder that weakens the heart and skeletal muscle.
What happened in the dish
The team irradiated two kinds of heart cells: a rat cardiomyoblast line called H9C2 and human heart-muscle cells (hiPSC-CMs) grown from reprogrammed stem cells. Gamma radiation at 2, 5, and 10 Gray (a Gray is the unit of absorbed radiation dose) slowed the cells' growth more at each higher dose and switched on the classic aging stain, a blue color that marks senescent cells.
Adding SS-31 at 1 micromolar for seven days changed the picture. Under the heaviest 10 Gray dose, the fraction of cells staining positive for the aging marker fell from 67 percent to 38 percent. The peptide also blocked the rise of p16 and p21, two proteins that lock a cell out of the cell cycle, and it lowered three inflammatory signals of the senescence-associated secretory phenotype that senescent cells pump out: TNF-alpha, IL-6, and IL-1beta. It nudged the BAX to bcl-2 ratio, a readout of the cell's built-in suicide machinery, back toward normal, and it cut the surge of reactive oxygen species inside the mitochondria. A 10 Gray dose also drove mitochondrial respiration up abnormally, and the peptide brought that back down as well.
What it does not show yet
This is a cell study, not an animal or human one. Every number comes from cells in a dish, and the authors frame the peptide as promising rather than proven. Whether an intact heart getting radiation alongside a tumor would see the same protection, and whether shielding irradiated cells from senescence might blunt the radiation's effect on the tumor next door, are open questions the paper does not answer.
Still, the mechanism is specific and the drug already exists in people. Elamipretide is one of a small set of mitochondria-targeted ↗ peptides on peptidemodel, tied to the cardiolipin ↗ target, and the same membrane-stabilizing trick that earned it a Barth syndrome approval is what the radiation study leans on. A drug that is already through the safety gate for one heart condition is a shorter path to test against another.